First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

Inclusion Criteria: * Histologically confirmed WHO Grade 4 astrocytoma from archival tissue. IDH mutation status and MGMT promoter methylation status will not limit candidacy but needs to be known. * Evidence of first or second cancer recurrence/ progression by magnetic resonance imaging (MRI) for which a gross tumor resection (GTR) is feasible as determined by the primary investigator in concordance with the study-affiliated neurosurgeon. * Previous completed SOC antitumor treatment including surgery, radiation therapy, and temozolomide +/- Optune/ Tumor Treatment Fields (TTF). * No concurrent alternative curative therapy, including use of TTF. * Able to undergo standard MRI scans with contrast agent throughout the course of the study. * ≥ 18 years and ≤ 75 years of age at the time of consent. * Karnofsky performance status ≥70. * Must be completely off or on a dose of dexamethasone 2mg daily or less with stable neurological function at the time of enrollment. * Adequate organ function within 14 days of study treatment start as defined in Section 4.1.9 of the protocol. * Participants of childbearing potential (POCBP) or with partners of childbearing potential must use a highly effective form of contraception from the time of the screening visit until at least 3 months after the dose of FT536. * Must agree to and sign the consent for the companion Long-Term Follow-Up study (CPRC# 2021LS077). * Voluntary written consent prior to the performance of any research related procedu…